Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Dec;44(12):3478-80.
doi: 10.1128/AAC.44.12.3478-3480.2000.

Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species

Affiliations
Clinical Trial

Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species

H F Geerdes-Fenge et al. Antimicrob Agents Chemother. 2000 Dec.

Abstract

After oral administration of 500 mg of levofloxacin to 12 volunteers, we investigated the pharmacokinetics and serum bactericidal activities (SBAs) against five strains of members of the family Enterobacteriaceae. Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg. h/liter; elimination half-life 4.23 +/- 0.87 h. SBAs were present for 24 h against Escherichia coli and Citrobacter freundii. The SBAs at 1, 12, and 24 h after administration against E. coli were 1:108, 1:29, and 1:7, respectively, and those against Citrobacter freundii were 1:74, 1:25, and 1:7, respectively. The SBAs were present for 12 h against the other three organisms tested. The SBAs against Serratia marcescens were 1:28 and 1:9 at 1 and 12 h, respectively; the SBAs against Klebsiella pneumoniae were 1:25 and 1:7 at 1 and 12 h, respectively; and the SBAs against Enterobacter cloacae were 1:24 and 1:10 at 1 and 12 h, respectively.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
    1. Chien S C, Chow A T, Natarajan J, Williams R R, Wong F A, Rogge M C, Nayak R K. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 1997;41:1562–1565. - PMC - PubMed
    1. Chien S C, Rogge M C, Gisclon L G, Curtin C, Wong F, Natarajan J, Williams R R, Fowler C L, Cheung W K, Chow AT. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41:2256–2260. - PMC - PubMed
    1. Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis. 1998;26:1–12. - PubMed
    1. Davis R, Bryson H M. Levofloxacin—a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994;47:677–700. - PubMed

Publication types

LinkOut - more resources